268 related articles for article (PubMed ID: 25935542)
1. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
[TBL] [Abstract][Full Text] [Related]
2. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.
Clewemar Antonodimitrakis P; Sundin A; Wassberg C; Granberg D; Skogseid B; Eriksson B
Neuroendocrinology; 2016; 103(3-4):345-53. PubMed ID: 26279284
[TBL] [Abstract][Full Text] [Related]
3. Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.
Shibuya H; Hijioka S; Sakamoto Y; Ito T; Ueda K; Komoto I; Kobayashi N; Kudo A; Yasuda H; Miyake H; Arita J; Kiritani S; Ikeda M; Imaoka H; Ueno M; Kobayashi S; Furuta M; Nagashio Y; Murohisa G; Aoki T; Matsumoto S; Motoya M; Azemoto N; Itakura J; Horiguchi S; Yogi T; Kawagoe T; Miyaoka Y; Imamura F; Senju M; Arioka H; Hara K; Imamura M; Okusaka T
Cancer Chemother Pharmacol; 2018 Oct; 82(4):661-668. PubMed ID: 30054710
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
Ducreux M; Dahan L; Smith D; O'Toole D; Lepère C; Dromain C; Vilgrain V; Baudin E; Lombard-Bohas C; Scoazec JY; Seitz JF; Bitoun L; Koné S; Mitry E
Eur J Cancer; 2014 Dec; 50(18):3098-106. PubMed ID: 25454412
[TBL] [Abstract][Full Text] [Related]
5. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy.
Lahner H; Mathew A; Klocker AL; Unger N; Theysohn J; Rekowski J; Jöckel KH; Theurer S; Schmid KW; Herrmann K; Führer D
Endocrine; 2022 Jan; 75(1):293-302. PubMed ID: 34480724
[TBL] [Abstract][Full Text] [Related]
6. Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors.
Schrader J; Henes FO; Blaeker M; Zimmermann-Fraedrich K; Pace A; Perez D; Izbicki JR; Lohse AW; Benten D
Endocrine; 2019 Aug; 65(2):460-467. PubMed ID: 31037707
[TBL] [Abstract][Full Text] [Related]
7. Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy.
Krug S; Boch M; Nimphius W; Gress TM; Michl P; Rinke A
Pancreatology; 2017; 17(1):139-145. PubMed ID: 28027897
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.
Turner NC; Strauss SJ; Sarker D; Gillmore R; Kirkwood A; Hackshaw A; Papadopoulou A; Bell J; Kayani I; Toumpanakis C; Grillo F; Mayer A; Hochhauser D; Begent RH; Caplin ME; Meyer T
Br J Cancer; 2010 Mar; 102(7):1106-12. PubMed ID: 20234360
[TBL] [Abstract][Full Text] [Related]
9. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S; Gress TM; Michl P; Rinke A
Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
[TBL] [Abstract][Full Text] [Related]
10. Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin.
Gonzalez MA; Biswas S; Clifton L; Corrie PG
Br J Cancer; 2003 Aug; 89(3):455-6. PubMed ID: 12888810
[TBL] [Abstract][Full Text] [Related]
11. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
Sun W; Lipsitz S; Catalano P; Mailliard JA; Haller DG;
J Clin Oncol; 2005 Aug; 23(22):4897-904. PubMed ID: 16051944
[TBL] [Abstract][Full Text] [Related]
12. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.
Ono H; Kudo A; Akahoshi K; Ogura T; Ogawa K; Ban D; Tanaka S; Tanabe M
J Cancer Res Clin Oncol; 2020 Mar; 146(3):793-799. PubMed ID: 31844980
[TBL] [Abstract][Full Text] [Related]
13. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
14. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series.
Müller C; Kreissl MC; Klose S; Krause A; Keitel V; Venerito M
Medicine (Baltimore); 2022 Jan; 101(4):e28610. PubMed ID: 35089197
[TBL] [Abstract][Full Text] [Related]
16. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.
Kouvaraki MA; Ajani JA; Hoff P; Wolff R; Evans DB; Lozano R; Yao JC
J Clin Oncol; 2004 Dec; 22(23):4762-71. PubMed ID: 15570077
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Walter T; Bruneton D; Cassier PA; Hervieu V; Pilleul F; Scoazec JY; Chayvialle JA; Lombard-Bohas C
Clin Colorectal Cancer; 2010 Oct; 9(4):248-54. PubMed ID: 20920998
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Lamarca A; Elliott E; Barriuso J; Backen A; McNamara MG; Hubner R; Valle JW
Cancer Treat Rev; 2016 Mar; 44():26-41. PubMed ID: 26855376
[TBL] [Abstract][Full Text] [Related]
20. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin.
Jann H; Denecke T; Koch M; Pape UF; Wiedenmann B; Pavel M
Neuroendocrinology; 2013; 98(2):137-43. PubMed ID: 23797176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
